Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950481 · ClinicalTrials.gov registry record · Phase 1
Effect of Hepatic Impairment on LDK378 Pharmacokinetics
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01950481 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT01950481, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Pharmacokinetics and safety of 750 mg of LDK378 given once orally in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
Interventions
- DRUG LDK378
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01950481
The ClinicalTrials.gov registry entry for NCT01950481 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LDK378 is the first listed.
NCT01950481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01950481 about?
NCT01950481 is a clinical study titled "Effect of Hepatic Impairment on LDK378 Pharmacokinetics". Pharmacokinetics and safety of 750 mg of LDK378 given once orally in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
What is the current status of trial NCT01950481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2014-01. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01950481?
The interventions under investigation include: LDK378 (DRUG).
Who is sponsoring clinical trial NCT01950481?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.